0 views left Get unlimited views with a free account
Subscribe to GlobalData Explorer
Get a 360 degree view on a company powered by live data from the GlobalData Intelligence Center.

Novartis: Q2 2022 Earnings Update

  • Industry: Healthcare
  • Current: Company Performance
  • Novartis reported a decrease in sales of 1.4% in Q2 2022 on an annual basis but grew 5% on constant currency basis
  • Novartis reported earnings per share (EPS) of $0.77
  • Novartis reiterated mid-single digit sales growth in 2022

On July 19, 2022, Novartis reported Q2 sales of $12.8 billion (a decrease of 1.4% year-over-year, a +5% constant currency growth) on core earnings per share (EPS) of $1.56.

Summary: Novartis’s Q2 2022 sales declined 1.4% as compared to the same period in 2021. Novartis reports its sales across two segments: Innovative Medicines and Sandoz.

  • Innovative Medicines business declined by 0.9% vs 2021 (+5% constant currency growth). While Entresto, Kesimpta, Cosentyx, Kisqali and Zolgensma showed a strong sales growth, but generic competition impacted drugs like Afinitor/Votubia (46% drop in YoY sales), Gleevec/Glivec (21% drop in YoY sales), Exjade, Gilenya (ex-US, 23% drop in YoY sales) and Exforge (19% drop in YoY sales). Pricing had negative impact of 4 percentage points, whereas volume contributed to 13 percentage points in growth.
  • Sandoz business declined by 3.2% vs 2021 (+5% constant currency growth). Pricing had negative impact of 6 percentage points, whereas volume contributed to 11 percentage points in growth.

The company reported an core operating income of $4.27 billion during Q2 2022, a year-over-year decrease of 2%. On the bottom line, the company reported a EPS of $0.77, whereas the core earnings came to $1.56 per share.

Guidance: Novartis’ guidance for the full year 2022 (in constant currency):

  • Sales expected to grow mid-single digit
  • Core operating income expected to grow mid-single digit
  • Innovative Medicines:
    • Sales expected to grow mid-single digit
    • Core operating income expected to grow mid to high single digit, ahead of sales
  • Sandoz:
    • Sales expected to grow low single digit (revised upwards from broadly in line)
    • Core operating income expected to be broadly in line with prior year (revised upwards from to decline low to mid-single digit)
Get a 360 degree view on a company powered by live data from the GlobalData Intelligence Center. Get a 360 degree view on a company powered by live data from the GlobalData Intelligence Center. Explore Company Solutions

Related Data & Insights

Novartis AG – Risk Profile
Switzerland Healthcare
F. Hoffmann-La Roche Ltd – Risk Profile
Switzerland Healthcare

Related Companies

Optum Inc

United States of America

Evernorth Health Inc

United States of America

Johnson & Johnson

United States of America

Sinopharm Group Co Ltd

China

HCA Healthcare Inc

United States of America

Eli Lilly and Co

United States of America

Merck & Co Inc

United States of America

Pfizer Inc

United States of America

AbbVie Inc

United States of America

AstraZeneca Plc

United Kingdom

Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer